A new analysis suggests that these AI-assessed scores could help identify patients at elevated cardiovascular risk even when their coronary calcium levels are low or absent on imaging.
Cardiologist Philippe Généreux spoke to Cardiovascular Business about the highly anticipated PROGRESS trial. "What we learned from this trial is that moderate aortic stenosis should not be seen anymore as a benign entity," he said.
More and more clinicians are using advanced CCTA technologies to diagnose, treat and manage patients with suspected coronary artery disease. An upcoming webinar will include a deep dive into that very topic, highlighting why the modality is such a game-changer for patient care.
A new AI-powered voice analysis system is much more accurate than the current standard of care, according to new data presented at AHA Scientific Sessions 2026. The technology was specifically built to be user-friendly, requiring patients to speak just a handful of sentences into their smartphone each day.
The UltiSynq defibrillation lead from Abbott gives clinicians a new option for left bundle branch area pacing. The device has also received CE mark approval.
While quality-of-life improvements were seen in patients with regular chest pain, an invasive treatment strategy was not associated with a significant improvement in survival compared to patients treated more conservatively.
Curtiss Stinis, MD, has been performing TAVR for nearly two decades. He says the new policies from CMS that expand coverage for asymptomatic patients represent a "momentous step forward" for heart patients with severe aortic stenosis.
